[1]
Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde. Clin Anat 8(6): 429-31.(1995);
[2]
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3): 263-9.(2011);
[3]
Frisoni GB, Bocchetta M, Chetelat G, Rabinovici GD, de Leon MJ, Kaye J, et al. Imaging markers for Alzheimer disease: which vs. how. Neurology 81(5): 487-500.(2013);
[4]
Cordell B. beta-Amyloid formation as a potential therapeutic target for Alzheimer’s disease. Annu Rev Pharmacol Toxicol 34: 69-89.(1994);
[5]
Zimmermann M, Gardoni F, Di Luca M. Molecular rationale for the pharmacological treatment of Alzheimer’s disease. Drugs Aging 1: 27-37.(2005);
[6]
Geldenhuys WJ, Darvesh AS. Pharmacotherapy of Alzheimer’s disease: Current and future trends. Expert Rev Neurother 15(1): 3-5.(2014);
[7]
Murphy MP, LeVine H III. Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis 19(1): 311-23.(2010);
[8]
Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12(10): 383-8.(1991);
[9]
Tabaton M, Cammarata S, Manetto V, Perry G, Mancardi G. Tau-reactive neurofibrillary tangles in cerebellar cortex from patients with Alzheimer’s disease. Neurosci Lett 103(3): 259-62.(1989);
[10]
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256(5054): 184-5.(1992);
[11]
Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18(4): 351-7.(1997);
[12]
Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 26(27): 7212-21.(2006);
[13]
Turner PR, O’Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70(1): 1-32.(2003);
[14]
Hiltunen M, van Groen T, Jolkkonen J. Functional roles of amyloid-beta protein precursor and amyloid-beta peptides: evidence from experimental studies. J Alzheimers Dis 18(2): 401-12.(2009);
[15]
Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268(32): 24374-84.(1993);
[16]
Tabaton M, Mandybur TI, Perry G, Onorato M, Autilio-Gambetti L, Gambetti P. The widespread alteration of neurites in Alzheimer’s disease may be unrelated to amyloid deposition. Ann Neurol 26(6): 771-8.(1989);
[17]
Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 3: 2-3.(2005);
[18]
Ashford JW, Salehi A, Furst A, Bayley P, Frisoni GB, Jack CR Jr, et al. Imaging the Alzheimer brain. J Alzheimers Dis 3: 1-27.(2011);
[19]
Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349(6311): 704-6.(1991);
[20]
Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9): 698-712.(2011);
[21]
Hampel H. Amyloid-β and cognition in aging and Alzheimer’s disease: Molecular and neurophysiological mechanisms. J Alzheimers Dis 33(1): S79-86.(2013);
[22]
Iqbal K, Del C, Alonso A, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739(2): 198-210.(2005);
[23]
Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging 24(8): 1063-70.(2003);
[24]
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate alzheimer’s disease. N Engl J Med 370(4): 311-21.(2014);
[25]
Gauthier SG. Alzheimer’s disease: the benefits of early treatment. Eur J Neurol 12(3): 11-6.(2005);
[26]
Guo S, Getsios D, Hernandez L, Cho K, Lawler E, Altincatal A, et al. Florbetaben PET in the early diagnosis of Alzheimer’s disease: a discrete event simulation to explore its potential value and key data gaps. Int J Alzheimers Dis 2012 548157(2012);
[27]
Patt M, Schildan A, Barthel H, Becker G, Schultze-Mosgau MH, Rohde B, et al. Metabolite analysis of [18F]Florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial. J Radioanal Nucl Chem 284: 557-62.(2010);
[28]
Lide D. CRC Handbook of Chemistry and Physics. 76th ed. USA: CRC Press Inc. (1995).
[29]
Mason NS, Mathis CA, Klunk WE. Positron emission tomography radioligands for in vivo imaging of Abeta plaques. J Labelled Comp Radiopharm 56(3-4): 89-95.(2013);
[30]
Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol 32(8): 799-809.(2005);
[31]
Wang H, Guo X, Jiang S, Tang G. Automated synthesis of [18F]Florbetaben as Alzheimer’s disease imaging agent based on a synthesis module system. Appl Radiat Isot 71(1): 41-6.(2013);
[33]
Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, et al. In vitro characterization of [18F]-florbetaben, an Abeta imaging radiotracer. Nucl Med Biol 39(7): 1042-8.(2012);
[34]
Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7(2): 129-35.(2008);
[35]
Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: Phase 3 study. Alzheimers Dement 28(15)11(8): 964-74.(2015);
[36]
Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 11(8): 669-78.(2012);
[37]
Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, et al. Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging 38(9): 1702-14.(2011);
[38]
Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbetaben binding to beta-amyloid deposits in human brains. J Nucl Med 54(5): 723-31.(2013);
[39]
Jennings D, Seibyl J, Sabbagh M, Lai F, Hopkins W, Bullich S, et al. Age dependence of brain beta-amyloid deposition in Down syndrome: An [18F]florbetaben PET study. Neurology 84(5): 500-7.(2015);
[40]
O’Keefe GJ, Saunder TH, Ng S, Ackerman U, Tochon-Danguy HJ, Chan JG, et al. Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 50(2): 309-15.(2009);
[41]
Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37(1): 181-200.(2010);
[42]
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 10(5): 424-35.(2011);
[43]
Tiepolt S, Barthel H, Butzke D, Hesse S, Patt M, Gertz HJ, et al. Influence of scan duration on the accuracy of beta-amyloid PET with florbetaben in patients with Alzheimer’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging 40(2): 238-44.(2013);
[44]
Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, et al. Abeta imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry 86(4): 431-6.(2015);
[45]
Jaskowiak CJ, Bianco JA, Perlman SB, Fine JP. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med 46(3): 424-8.(2005);
[46]
Mann DM, Jones D, Prinja D, Purkiss MS. The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down’s syndrome and Alzheimer’s disease. Acta Neuropathol 80(3): 318-27.(1990);
[47]
van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med 54(9): 1570-6.(2013);
[48]
Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodriguez Martinez de Llano S, Edison P, et al. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 134(Pt 1): 293-300.(2011);
[49]
Chiaravalloti A, Pagani M, Micarelli A, Di Pietro B, Genovesi G, Alessandrini M, et al. Cortical activity during olfactory stimulation in multiple chemical sensitivity: a (18)F-FDG PET/CT study. Eur J Nucl Med Mol Imaging 42(5): 733-40.(2015);
[50]
Chiaravalloti A, Martorana A, Koch G, Toniolo S, di Biagio D, di Pietro B, et al. Functional correlates of t-Tau, p-Tau and Abeta1-42 amyloid cerebrospinal fluid levels in Alzheimer’s disease: a 18F-FDG PET/CT study. Nucl Med Commun 36(5): 461-8.(2015);
[51]
Perani D, Schillaci O, Padovani A, Nobili FM, Iaccarino L, Della Rosa PA, et al. A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. BioMed Res Int 2014 785039(2014);
[52]
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 58(12): 1985-92.(2001);
[53]
Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G, et al. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing swedish mutant β-Amyloid precursor protein using 18F-florbetaben PET. J Nucl Med 54(7): 1127-34.(2013);
[54]
Petersen RC, Waring SC, Smith GE, Tangalos EG, Thibodeau SN. Predictive value of APOE genotyping in incipient Alzheimer’s disease. Ann New York Acad Sci 802: 58-69.(1996);
[55]
Ong K, Villemagne VL, Bahar-Fuchs A, Lamb F, Chetelat G, Raniga P, et al. (18)F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimers Res Ther 5(1): 4.(2013);
[56]
Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 52(8): 1210-7.(2011);
[57]
Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, et al. Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 74(6): 905-13.(2013);
[58]
Barthel H, Sabri O. Florbetaben to trace amyloid-beta in the Alzheimer brain by means of PET. J Alzheimers Dis 26(3): 117-21.(2011);
[59]
Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 9(5): S72-83.(2013);
[60]
Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 68(20): 1718-25.(2007);
[61]
Schipke CG, Peters O, Heuser I, Grimmer T, Sabbagh MN, Sabri O, et al. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer’s disease. Dement Geriatr Cogn Disord 33(6): 416-22.(2012);
[62]
Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 78(7): 477-84.(2012);
[63]
Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132(Pt 5): 1355-65.(2009);
[64]
Sojkova J, Zhou Y, An Y, Kraut MA, Ferrucci L, Wong DF, et al. Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch Neurol 68(5): 644-9.(2011);
[65]
Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TL, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 70(5): 857-61.(2011);
51
6